Incyte Genomics, Inc. (INCY) Posts Narrower than Expected Q3 Loss
Incyte Genomics, Inc. (NASDAQ: INCY) reported Q3 loss of ($0.42), $0.03 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $16.54 million.